Still the potential Prochymal?

Disappointing is the news today that Prochymal, Osirus Therapeutics mesenchymal stem cells (MSC) therapy, failed in late stage clinical trials in acute Graft-versus-host disease (GvHD). GvHD is a serious difficulty that occurs in some people who received bone marrow from a donor. If the tests were successful, would probably be the first commercial product Prochymal stem cells, approved by the FDA.

However, there are still grounds for hope. First, in one of the trials of GvHD patients with GvHD affecting their liver or gastrointestinal tract, who did not respond to steroid treatment appeared to benefit from Prochymal, although results are still preliminary. In addition, Prochymal is still currently being tested in human trials for several other indications, including type 1 diabetes, heart attack, chronic obstructive pulmonary disease (COPD). The same kind of stem cells used for Prochymal as MSCs – are also in the dental pulp, currently extracted, privately held for families through our national laboratory of the dental pulp. We and many others will continue to track the news and hope for the best as possible stem cell treatment is tested in these areas.

Be the first to like this post.Tags: MSCs, NDPL

This entry was posted on September 9, 2009 at 4: 47 pm and is filed under the cord blood research. You can track any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback your own site.

cord blood us